IMS corrected it's week 4 data for Gilead's Harvoni prescriptions. You'll notice downward revisions in Harvoni TRx by 232 and NRx by 226, Harvoni + Sovaldi you'll see downward revisions in TRx by 392 and NRx by 285.
IMS corrected week 4 data for Gilead Sciences's (NASDAQ: GILD) Harvoni, noted a report by RBC analyst Michael J. Yee. The new data shows Harvoni TRx was 2633. NRx was 2542, up 29% week-over-week. Harvoni +Sovaldi TRx was 6547, and Harvoni +Sovaldi NRx was 3653, up 10%. "Despite the correction, Harvoni's week 4 NRx appears to be still tracking at a healthy pace, 2.5x vs. Sovaldi's NRx at week 4, which was 998 (albeit this was during week of New Years '13)," said Yee.
Disclosure: The author is long GILD.